Ajinomoto's $546M Acquisition of US-based Forge Biologics
jason tuinstra 4OfaTz6SdYs unsplash

Japan’s Ajinomoto agreed to acquire U.S.-based genetic medicines maker Forge Biologics Holdings for 82.8 billion yen ($546 million).

The transaction is expected to be completed in December 2023 pending regulatory approvals, Ajinomoto said a release.

Ajinomoto, whose primary business is in seasonings and processed foods, has a healthcare segment that focuses on drugs derived from amino acids.

Forge, based in the U.S. state of Ohio, is a contract development and manufacturing organization (CDMO) for gene-based therapies. Ajinomoto said Forge will integrate with its own AminoScience platform to work on new treatment options for rare diseases.

($1 = 151.7400 yen)

Source: Reuters

Related Articles

Investors/Business, General
Information, News
Prime Minister Kishida Fumio, during a speech in New York to over 200 US business leaders, expressed his commitment to invigorating foreign investment in Japan, particularly by creating specialized business zones tailored for asset management firms.
General, Investors/Business
The world’s third-largest economy ran a current account deficit of 132.4 billion yen ($980 million) in June, government data showed, reversing 872 billion yen from the same month a year earlier. The current account surplus has declined for four fiscal years in a row through March 2022. While yen weakness has inflated the cost of imports, its boost to the value of exports has not been as great as it once was due to an ongoing shift of exporters' production abroad.
Investors/Business, General
Information, News
ESR, a major player in the Asia Pacific industrial sector, is embarking on a groundbreaking venture with a 3.3 million sqft logistics project in Greater Tokyo. This development, ESR Higashi Ogishima Distribution Centre 2, is funded by the recently secured JPY 150 billion ($1.35 billion) ESR Japan Logistics Fund III, signaling continued support from an Asian investor who backed the preceding RJLF2 strategy.
Since Feb 2020, with the onset of the Covid-19 global pandemic, things have changed slightly - J-REITs, which tend to be far more liquid and volatile than their underlying assets due to their very nature, have been trending down significantly in their share cost to Net Asset Value (NAV) ratios...